Despite the continuous effort to understand the pathophysiology and determine potential
therapeutic targets, PCOS treatment largely depends on lifestyle intervention and …

Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of
reproductive age. This condition is characterized by hyperandrogenism and either oligo-or …

Objectives. Both glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and metformin
(MET) have markedly antiobesity effects in overweight/obese polycystic ovary syndrome …

Background: Obesity and insulin resistance (IR) are common in polycystic ovary syndrome
(PCOS), which contribute to reproductive and metabolic abnormalities. Metformin increases …

Introduction: Polycystic ovarian syndrome (PCOS) affects many women of child-bearing age
and is characterized by hyperandrogenism, ovulatory and metabolic dysfunction. A primary …

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females and
is often associated with a number of cardiometabolic disorders such as central obesity …

Polycystic ovary syndrome (PCOS) is a disorder that involves several organ systems and
cellular pathways. It is strongly influenced by environmental and epigenetic factors. The …

This meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide 1 (GLP-
1) receptor agonists for women with polycystic ovary syndrome (PCOS) by comparing their …

Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects
women of reproductive age. Metabolic consequences associated with PCOS include, but …

Purpose Glucagon-like peptides receptor agonists are currently approved as anti-obesity
agents, yet the experience with their use in polycystic ovarian syndromes (PCOS)-related …